



DR. NAKUL DILIP TIKARE

Associate Consultant - Clinical Haematology

Qualification

MBBS | MD in Internal Medicine | DM in Clinical Haematology

Overview

Dr. Nakul Dilip Tikare is a skilled haematologist with deep expertise in managing blood-related disorders and bone marrow conditions. He is currently working as an Associate Consultant in the Department of Clinical Haematology at Manipal Hospitals, Goa. With over a decade of experience in Internal Medicine and advanced training in Clinical Haematology, Dr. Nakul is known for his patient-focused approach and commitment to evidence-based care. Dr. Nakul completed his super-speciality training (DM) in Clinical Haematology from the prestigious AIIMS, Bhubaneswar. His earlier qualifications include an MD in Internal Medicine and an MBBS from Goa Medical College, Bambolim. Over the years, he has gained hands-on experience from top institutions such as SGPGI Lucknow and Rajiv Gandhi Cancer Institute, New Delhi. Dr. Nakul's areas of interest include bone marrow transplant (BMT), cellular therapy, Immunohaematology, and Haematologic cancers such as leukaemia, lymphoma, and multiple myeloma. He has also worked extensively on chronic myeloid leukaemia (CML) and disorders of thrombocytopenia. He has contributed to several national and international publications, with research featured in leading journals

like Clinical Lymphoma Myeloma Leukaemia, BMJ Case Reports, and Blood Journal. Dr. Nakul actively participates in medical conferences and MHG webinars. He is committed to continuous learning and regularly participates in academic discussions and clinical research. At Manipal Hospitals, Goa, he brings a strong combination of clinical knowledge, research experience, and compassionate care to treat complex blood-related disorders and improve patient outcomes.

Field of Expertise

- Anaemia and Haemoglobin Disorders
- Bone Marrow Transplant (BMT) & Cellular Therapy, including CAR-T
- Immunohaematology
- Haemato-oncology (Leukaemia, Lymphoma, Multiple Myeloma)
- Disorders of Platelets - including ITP
- Chronic Myeloid Leukaemia (CML)
- Bleeding disorders, including Haemophilia
- Thalassemia
- Myelodysplastic Syndrome (MDS)
- Treatment of Thrombotic Disorders
- Hematologic Complications of Pregnancy

Languages Spoken

- English
- Hindi
- Konkani
- Marathi

Awards & Achievements

- Presenter at multiple national-level conferences such as MHG Annual Conferences (2016, 2019, 2023, 2024), Best of ASH 2020
- Dr Nakul Dilip Tikare is a skilled haematologist with deep expertise in managing blood-related disorders and bone marrow conditions. He is currently working as an Associate Consultant in the Department of Clinical Haematology at Manipal Hospitals, Goa. With over a decade of experience in Internal Medicine and advanced training in Clinical Haematology, Dr Tikare is known for his patient-focused approach and commitment to evidence-based care.
- Selected to present multiple papers in the Blood journal (ASH abstracts), highlighting research in Hairy Cell Leukaemia, FLT3 mutated AML, and Dasatinib strategies

Talks & Publications

- Tikare N et al. Efficacy of low-dose dasatinib (50mg) in chronic myeloid leukaemia: Chronic phase (CML-CP) in LMIC—Are we there yet?. *Journal of Clinical Oncology* 2025
- Pritish P, Sujay R, Tikare N et al. Allogeneic transplantation for CML blast phase: Learnings over last decade from a single centre in North India. *Annals of Hematology* 2025
- Panigrahi C, Tikare N, et al. Core-binding factor abnormalities involving chromosome 16 in AML. *BMJ Case Reports* 2023.
- Sonali M, et al. Pediatric systemic mastocytosis with clonal non-mast cell neoplasm. *Am J Leuk Res* 2023.
- Soni A, Tikare N, et al. Real-world outcome of high-risk multiple myeloma. *Clin Lymphoma Myeloma Leuk* 2024.
- Panda T, Tikare N, et al. Rituximab + Cladribine in Hairy Cell Leukaemia. *Blood Journal* 2024.

- Singh R, Tikare N, et al. Dasatinib de-escalation in CML. Blood Journal 2024.
- Disha D, Tikare N, et al. Gilteritinib in FLT3-mutated r/r AML. Blood Journal 2024.
- Poster at MHG Annual Conference 2023 – Dasatinib adverse events mimicking ulcerative colitis.